5Giuseppe Mancia,Robert Fagard,Krzysztof Narkiewicz,Josep Redon,Alberto Zanchetti,Michael B?hm,Thierry Christiaens,Renata Cifkova,Guy De Backer,Anna Dominiczak,Maurizio Galderisi,Diederick E. Grobbee,Tiny Jaarsma,Paulus Kirchhof,Sverre E. Kjeldsen,Stéphane Laurent,Athanasios J. Manolis,Peter M. Nilsson,Luis Miguel Ruilope,Roland E. Schmieder,Per Anton Sirnes,Peter Sleight,Margus Viigimaa,Bernard Waeber,Faiez Zannad,Josep Redon,Anna Dominiczak,Krzysztof Narkiewicz,Peter M. Nilsson.2013 ESH/ESC Guidelines for the management of arterial hypertension[J]. European Heart Journal . 2013 (28)
6Derrick M. Van Rooyen,Lay T. Gan,Matthew M. Yeh,W. Geoffrey Haigh,Claire Z. Larter,George Ioannou,Narci C. Teoh,Geoffrey C. Farrell.Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome<!-- Doctopic: GMD -->[J].Journal of Hepatology.2013(1)
7Marcello Ricardo Paulista Markus,Sebastian Edgar Baumeister,Jan Stritzke,Marcus D?rr,Henri Wallaschofski,Henry V?lzke,Wolfgang Lieb.Hepatic Steatosis Is Associated With Aortic Valve Sclerosis in the General Population: The Study of Health in Pomerania (SHIP)[J].Arteriosclerosis Thrombosis and Vascular Biology.2013(7)
8Matti J. Tikkanen,Rana Fayyad,Ole Faergeman,Anders G. Olsson,Chuan-Chuan Wun,Rachel Laskey,John J. Kastelein,Ingar Holme,Terje R. Pedersen.Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels[J].International Journal of Cardiology.2013
9Giovanni Targher,Christopher D. Byrne.Nonalcoholic Fatty Liver Disease: A Novel Cardiometabolic Risk Factor for Type 2 Diabetes and Its Complications[J].The Journal of Clinical Endocrinology & Metabolism.2013(2)
10Lucia Carulli,Mauro Maurantonio,Lionel Hebbard,Enrica Baldelli,Paola Loria,Jacob George.Classical and Innovative Insulin Sensitizing Drugs for the Prevention and Treatment of NAFLD[J].Current Pharmaceutical Design.2013(29)
